Kenvue Brands LLC
To evaluate the antipyretic efficacy of a single dose of a fixed combination of acetaminophen/naproxen sodium, compared with placebo.
This will be a randomized, single-dose, double-blind, placebo-controlled, parallel-group study to evaluate the antipyretic efficacy and safety of a fixed-dose combination (FDC) of acetaminophen/naproxen sodium in adult subjects with endotoxin-induced fever, compared to placebo. The study will be conducted in two study phases (Phase A and Phase B), with the intent of Phase A being for endotoxin dose evaluation and the intent of Phase B being to evaluate the investigational product (IP)/placebo. Subjects enrolled in Phase A will not be included in Phase B, nor will data from these subjects be…
Inclusion Criteria Subjects must meet all of the following inclusion criteria in Sections A and B to be eligible for enrollment into the study: A) Assessed at Screening Visit (Visit 1): 1. Has a body mass index (BMI) of 17.5 to 37.0 (inclusive) for subjects who are 18 to 40 years old or a BMI of 17.5 to 35.0 (inclusive) for subjects who are 41 to 55 years old. 2. Healthy, defined as having no clinically relevant abnormalities or medical conditions identified by a detailed medical history; full physical examination; blood pressure, respiratory rate, and heart rate measurements; 12-lead ECG;…
The IP is to be taken as a single dose (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg) orally with 180 mL of room temperature water.
The placebo is to be taken as a single dose (administered as two tablets of placebo) orally with 180 mL of room temperature water.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.